Biopharmx Corp (BPMX) Shares Up 5.6%
Shares of Biopharmx Corp (NASDAQ:BPMX) shot up 5.6% during trading on Wednesday . The stock traded as high as $0.34 and last traded at $0.35. 903,201 shares changed hands during mid-day trading, an increase of 34% from the average session volume of 671,866 shares. The stock had previously closed at $0.33.
Several brokerages have commented on BPMX. Maxim Group restated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a report on Friday, June 2nd. Roth Capital set a $3.00 price objective on shares of Biopharmx Corp and gave the stock a “buy” rating in a report on Saturday, June 3rd. Finally, HC Wainwright set a $3.00 price objective on shares of Biopharmx Corp and gave the stock a “buy” rating in a report on Thursday, June 15th.
The firm’s market capitalization is $25.87 million. The stock’s 50-day moving average is $0.32 and its 200-day moving average is $0.49.
Biopharmx Corp (NASDAQ:BPMX) last issued its earnings results on Tuesday, June 13th. The company reported ($0.07) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.07). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. Equities research analysts predict that Biopharmx Corp will post ($0.31) EPS for the current fiscal year.
In other Biopharmx Corp news, major shareholder Franklin Resources Inc purchased 250,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average price of $0.34 per share, with a total value of $85,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu KCG Holdings LLC lifted its position in shares of Biopharmx Corp by 366.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after purchasing an additional 395,424 shares during the period. Vivo Capital LLC lifted its position in shares of Biopharmx Corp by 10.0% in the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after purchasing an additional 1,282,052 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Biopharmx Corp by 324.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after purchasing an additional 1,478,338 shares during the period.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.